Jan Pinkas
Technik-/Wissenschafts-/F&E-Leiter bei PYXIS ONCOLOGY, INC.
Profil
Jan Pinkas is currently the Chief Scientific Officer at Pyxis Oncology, Inc. He previously worked as the VP-Translational Research & Development at ImmunoGen, Inc. and as the Senior Vice President-Translation Services at Magenta Therapeutics, Inc. Dr. Pinkas received his undergraduate degree from The Johns Hopkins University and his doctorate degree from the University of Massachusetts.
Aktive Positionen von Jan Pinkas
| Unternehmen | Position | Beginn |
|---|---|---|
| PYXIS ONCOLOGY, INC. | Technik-/Wissenschafts-/F&E-Leiter | 12.04.2022 |
Ehemalige bekannte Positionen von Jan Pinkas
| Unternehmen | Position | Ende |
|---|---|---|
| IMMUNOGEN, INC. | Corporate Officer/Principal | - |
| MAGENTA THERAPEUTICS | Corporate Officer/Principal | - |
Ausbildung von Jan Pinkas
| University of Massachusetts | Doctorate Degree |
| The Johns Hopkins University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| PYXIS ONCOLOGY, INC. | Health Technology |
| IMMUNOGEN, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Magenta Therapeutics, Inc.
 Magenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. Its platform includes MGTA-117, MGTA-145, and CD45-ADC. The company was founded by David T. Scadden, Derrick J. Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 17, 2015 and is headquartered in Cambridge, MA. | Health Technology |
